SAB Biotherapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
| For The Three Months Ended September 30, | For The Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | ||||
| Grant revenue | $— | $— | $— | $1,207,712 |
| Total revenue | — | — | — | 1,207,712 |
| Operating expenses | ||||
| Research and development | 8,970,010 | 7,830,745 | 23,623,991 | 22,599,998 |
| General and administrative | 3,708,959 | 3,478,621 | 9,559,141 | 11,509,394 |
| Total operating expenses | 12,678,969 | 11,309,366 | 33,183,132 | 34,109,392 |
| Loss from operations | (12,678,969) | (11,309,366) | (33,183,132) | (32,901,680) |
| Other income (expense) | ||||
| Changes in fair value of warrant liabilities | 61,598,908 | 6,171 | 66,007,621 | 7,691,363 |
| Interest expense | (43,292) | (78,036) | (177,202) | (247,525) |
| Interest income | 655,233 | 277,174 | 731,293 | 1,149,624 |
| Other income | 765,881 | 754,647 | 1,608,138 | 1,597,608 |
| Warrant Issuance Cost | (4,852,292) | — | (4,852,292) | — |
| Total other income | 58,124,438 | 959,956 | 63,317,558 | 10,191,070 |
| Net income (loss) | $45,445,469 | $(10,349,410) | $30,134,426 | $(22,710,610) |
| Other comprehensive income (loss): | ||||
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | $87,751 | $44,172 | $87,104 | $574 |
| Foreign currency translation gain (loss) | $(723) | $39,314 | 119,529 | 25,139 |
| Total comprehensive income (loss) | $45,532,497 | $(10,265,924) | $30,341,059 | $(22,684,897) |
| Income (loss) per common share attributable to the Company’s shareholders | ||||
| Basic income (loss) per common share | $0.50 | $(1.12) | $0.73 | $(2.45) |
| Diluted income (loss) per common share | $(0.21) | $(1.12) | $(0.33) | $(2.45) |
| Weighted-average common shares outstanding – basic | 10,660,500 | 9,259,192 | 9,750,531 | 9,252,095 |
| Weighted-average common shares outstanding – diluted | 77,863,263 | 9,259,192 | 30,302,890 | 9,252,095 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.